Abstract: The common therapy of colorectal cancer is FOLFOX scheme, which contains flurouracil, leucovorin and oxaliplatin. Numerous clinical trials have demonstrated that bevacizumab combined with FOLFOX scheme in cancer's therapy is safe and effective. But the adverse reactions including hypertension, neurovirulence, gastrointestinal bleeding and perforation are raised up. Scholars have carried out a series of studies for the overall survival times, tumor response rates and survival qualities for the patients with metastatic colorectal cancer which using the joint scheme, but they draw different conclusions The usefulness and safety of the joint scheme still need more RCT and meta-ananlysis to be proved.

Key words: Colorectal neoplasms, Drug therapy, Bevacizumab